Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Credo Technology Group Holding Ltd (CRDO) vs Novo Nordisk A/S (NVO) Price & Performance

Credo Technology Group Holding LtdTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Credo Technology Group Holding Ltd vs Novo Nordisk A/S — how do they compare? Credo Technology Group Holding Ltd trades at $267.74 (market cap $46.19B), while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 4.5× Credo Technology Group Holding Ltd's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.

CRDONVO
Market Cap
$46.19B$207.85B
Sector
TechnologyHealth
52-Week High
$302.52$63.98
52-Week Low
$87.81$35.29
Enterprise Value
$44.77B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Credo Technology Group Holding Ltd

CRDO trades at $268.16, up 11.76% in 24 hours, with a bullish technical signal and strong institutional interest. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.16 exceeding expectations. Revenue surged to $436.78 million in 2025, and net income margin expanded to 35.37% in 2026. Positive news highlights Credo's role in AI infrastructure, including contributions to the Open Compute Project.

Outlook is positive due to AI-driven demand and strong financials, but risks include premium valuations (P/E 98.68) and customer concentration. Analyst consensus is bullish with a $285.42 price target. Investors should monitor execution risks and market volatility amid high growth expectations.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Credo Technology Group Holding Ltd

Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.

Read more on CRDO

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO